India-based Cipla Limited (BSE: 500087) (NSE: CIPLA EQ), a global pharmaceutical company, announced on Thursday that it has received final approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05%.
The product is an AB-rated generic therapeutic equivalent version of Novartis Pharmaceuticals Corporation's Durezol. It will be available for shipping soon.
Difluprednate Ophthalmic Emulsion 0.05% is utilised for the treatment of inflammation and pain associated with ocular surgery and endogenous anterior uveitis.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling